Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 32Gastrointestinal 26CNS 12Sarcoma 9Head & Neck 8Genitourinary 7Gynecologic 6Other solid neoplasm 3Breast 3Tumor-Agnostic 1Other neoplasm 1

Conditions

Precancerous Conditions 1Esophageal Neoplasms 1Barrett Esophagus 1

Interventions

Sulindac 4Biopsy 4Carboplatin 3Vaginal Smears 2Specimen Handling 2Cyclophosphamide 2Colposcopy 2Aspirin 2tipifarnib 1tanespimycin 1sargramostim 1radium Ra 223 dichloride 1pirfenidone 1fludarabine phosphate 1alethine 1X-Rays 1Taxes 1Sorafenib 1Resistance Training 1Radiotherapy 1Polymerase Chain Reaction 1Photons 1Peripheral Blood Stem Cell Transplantation 1Papanicolaou Test 1Paclitaxel 1Mycophenolic Acid 1Microarray Analysis 1Magnetic Resonance Spectroscopy 1Lovastatin 1Interleukin-12 Subunit p35 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Erlotinib Hydrochloride × Other neoplasm × Clear all
NCT00566800 2013-09-17

Erlotinib in Treating Patients With Barrett Esophagus

National Cancer Institute (NCI)

Phase 1 Unknown
25 enrolled
GastrointestinalOther neoplasm

Barrett Esophagus, Esophageal Neoplasms, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡